MétaCan
Menu
Back to cohort

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

2024· article· en· W4400018844 on OpenAlexafffund
Tania Jain, Noel Estrada‐Merly, María Queralt Salas, Soyoung Kim, Jakob D. DeVos, Min Chen, Xi Fang, Rajat Kumar, Marcio Andrade‐Campos, Hany Elmariah, Vaibhav Agrawal, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen K. Ballen, Amer Beitinjaneh, Vijaya Raj Bhatt, Christopher Bredeson, Zachariah DeFilipp, Bhagirathbhai Dholaria, Nosha Farhadfar, Shatha Farhan, Arpita Gandhi, Siddhartha Ganguly, Usama Gergis, Michael R. Grunwald, Nada Hamad, Betty K. Hamilton, Yoshihiro Inamoto, Madiha Iqbal, Omer Jamy, Mark Juckett, Mohamed A. Kharfan‐Dabaja, Maxwell M. Krem, Deepesh Lad, Jane L. Liesveld, Monzr M. Al Malki, Adriana K. Malone, Hemant S. Murthy, Guillermo Ortı́, Sagar S. Patel, Attaphol Pawarode, Miguel‐Angel Perales, Marjolein van der Poel, Olle Ringdén, David A. Rizzieri, Alicia Rovó, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Melhem Solh, Celalettin Üstün, Leo F. Verdonck, John R. Wingard, Baldeep Wirk, Nelli Bejanyan, Richard J. Jones, Taiga Nishihori, Betül Oran, Ryotaro Nakamura, Bart L. Scott, Wael Saber, Vikas Gupta

Bibliographic record

VenueBlood Advances · 2024
Typearticle
Languageen
FieldMedicine
TopicMyeloproliferative Neoplasms: Diagnosis and Treatment
Canadian institutionsUniversity of CalgaryUniversity of British ColumbiaOttawa HospitalPrincess Margaret Cancer Centre
FundersCancer MoonshotNational Institute of Environmental Health SciencesNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchLegend BiotechPharmacyclicsTakeda OncologyHealth Resources and Services AdministrationNational Institutes of HealthMorphoSysSeagenAstellas PharmaAdaptive BiotechnologiesPfizerIncyteKiadis Pharmabluebird bioMedacJazz PharmaceuticalsBeiGeneHistoGeneticsAtara BiotherapeuticsCareDxActinium PharmaceuticalsNational Cancer InstituteGilead SciencesMoonshot Research and Development ProgramSanofiGlaxoSmithKlineCSL BehringBristol-Myers SquibbAstraZenecaGateway for Cancer ResearchSwedish Orphan BiovitrumOmeros CorporationVertex PharmaceuticalsAlexion PharmaceuticalsMallinckrodt PharmaceuticalsAstellas Pharma USAmgenNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals Corporation
KeywordsMedicineHazard ratioInternal medicineConfidence intervalMyelofibrosisTransplantationGastroenterologySurgeryHematopoietic cellBone marrowHaematopoiesisStem cell

Abstract

fetched live from OpenAlex

ABSTRACT: We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In all 1597 patients, the use of haploidentical donors increased from 3% in 2013 to 19% in 2019. In study-eligible 1032 patients who received peripheral blood grafts for chronic-phase myelofibrosis, 38% of recipients of haploidentical HCT were non-White/Caucasian. Matched sibling donor (MSD)-HCTs were associated with superior overall survival (OS) in the first 3 months (haploidentical hazard ratio [HR], 5.80 [95% confidence interval (CI), 2.52-13.35]; matched unrelated (MUD) HR, 4.50 [95% CI, 2.24-9.03]; mismatched unrelated HR, 5.13 [95% CI, 1.44-18.31]; P < .001). This difference in OS aligns with lower graft failure with MSD (haploidentical HR, 6.11 [95% CI, 2.98-12.54]; matched unrelated HR, 2.33 [95% CI, 1.20-4.51]; mismatched unrelated HR, 1.82 [95% CI, 0.58-5.72]). There was no significant difference in OS among haploidentical, MUD, and mismatched unrelated donor HCTs in the first 3 months. Donor type was not associated with differences in OS beyond 3 months after HCT, relapse, disease-free survival, or OS among patients who underwent HCT within 24 months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. Although MSD-HCTs were superior, there is no significant difference in HCT outcomes from haploidentical and MUDs. These results establish haploidentical HCT with posttransplantation cyclophosphamide as a viable option in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.299
Teacher spread0.288 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations13
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicMyeloproliferative Neoplasms: Diagnosis and TreatmentFrench-language works237,207